Antifibrogenic role of the cannabinoid receptor CB2 in the liver. - Wikidata - wikimedia - TriplyDB

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

http://www.wikidata.org/entity/Q46376137

about

Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells Peripheral cannabinoid receptor, CB2, regulates bone mass.Is lipid signaling through cannabinoid 2 receptors part of a protective system?Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation The endocannabinoid system as an emerging target of pharmacotherapy Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C Extracellular matrix and liver disease The role of endocannabinoids system in fatty liver disease and therapeutic potentials Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver Developmental origins of NAFLD: a womb with a clue.Current status of novel antifibrotic therapies in patients with chronic liver disease Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study.Targeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.Cannabinoids as novel anti-inflammatory drugs.Hepatitis C virus induces the cannabinoid receptor 1.Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.Role of cannabinoids in the development of fatty liver (steatosis)Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.CB2: a cannabinoid receptor with an identity crisis CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state.Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis.Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease.The alpha subunit of Go modulates cell proliferation and differentiation through interactions with Necdin.Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.Recent advances in the understanding of the role of the endocannabinoid system in liver diseases.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.Endocannabinoids in liver disease.

P2860

Q21144343-A15F9B9D-3C61-4705-A5DC-BAEFFF16C491 Q24536360-9047CEC2-C0C5-42CC-AFB3-CC2285AF8DBC Q24633122-A8857C59-3390-40A3-A58A-62526F3BA36C Q24643922-CFA16091-D415-4287-B813-4CD1EF8A1F8B Q24648473-511BF8D5-B0E5-44F7-98FF-BC3726F2ADF1 Q26781789-BE06161D-AB06-4732-AD81-9FE51C6CD053 Q26823060-F5588E35-EB80-4654-A121-ACF062F0B06E Q27009466-AEF9D991-CF10-46D9-85A0-B9C0EB5780D7 Q27021577-29CEA1A7-4FAA-4873-B133-A4B15268C1AE Q27324350-ED6B1037-57CB-43FF-A807-797596A6269A Q28077583-A4EED62A-CAAD-427E-A4D9-38D7DE474350 Q28082065-35B2F97A-EFD8-4E7D-B1EA-F1C4AA8D4ADB Q28569215-9621211E-014F-4600-AE4D-41499E9229C7 Q29616840-EEDE7489-542B-4E99-87A9-B9FEFD3919AD Q30241940-40B0E3A7-8768-4C77-810D-D78C383ABC0A Q30473375-0BD16564-0270-4CE4-AB98-802A9481C8C1 Q33464957-6B334548-F3A0-4E7D-B314-807FDDEE5913 Q33602403-8212AD70-7454-43FC-BBB4-896B5E10B864 Q33655394-3276741B-B8E3-44A2-9BF5-A3CDA0E7A3C7 Q33687100-B15DB311-F4CC-4D67-80A5-2F7D35E63C43 Q33688381-92EA2A7E-A41F-4089-A002-B6D2E1AFA3A3 Q33700418-36DBAC80-999F-4753-8299-9BB08D197D1E Q33714587-E89D4B69-3E39-4F96-B971-80C7F7886DD0 Q33749478-D4C8F750-3198-4E17-B80D-998B0D8AC2D5 Q33920996-A94B0ED8-EB9A-482C-BCE0-FDC537D5F99A Q33947213-AE85D8D0-3FAA-492F-BD05-0311A4FDD160 Q34069579-C7B12764-4551-4AA8-BB83-104152318251 Q34098185-37AB03F7-1520-44A6-8687-DB6417FD8257 Q34098258-B3D35AA8-138E-4099-B26B-1ABDD9BA5325 Q34098271-2BAF14D8-C447-42B6-A1B7-A3A3534679BF Q34155467-7E84DD19-B71E-4701-97DF-30208C8A932E Q34358271-58567A52-E271-4B5E-A8BF-BCC670C4CF9D Q34395446-F9B79975-5C8C-4F3C-BEA3-782CCEB22193 Q34485623-2AD9D8A4-234D-4BA6-838A-C6166F8B36D7 Q34537906-977FFA14-4ACA-4DE2-96BE-5CB2B42107D3 Q34550846-7F79BF23-E3F3-4484-9243-D513CE1EB26B Q34647400-522BBE8C-C742-4190-924F-527F5AA8E38E Q34655802-493228E7-81F5-4BC7-A5F5-3F6ABCD41C01 Q34733645-CBDD655A-9813-427D-BFC3-43FFC0232F2A Q34776919-D73D1DDF-4A7D-4759-A3E4-2FE29734E9B2

P2860

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

http://www.wikidata.org/entity/Q46376137

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@en

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@nl

type

label

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@en

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@nl

prefLabel

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@en

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@nl

P1433

Q46376137-BD267F50-5047-49E0-9224-49717A2D8AE4

P1476

Q46376137-FD3622C5-C00A-47C4-8A97-595B426180CD

P2093

Q46376137-12F80780-4390-456A-8274-AF5F5837D191

Q46376137-245310EA-14AC-49E2-9F80-1531DE3B0463

Q46376137-34A01B40-77E9-43B9-B2E1-C1ED3685E6B6

Q46376137-64FA6AC4-3855-4DA2-8861-22038C3E0298

Q46376137-8CD0430F-4C1B-4A52-8E86-7182FE03C639

Q46376137-905763BD-8191-4E60-901C-67B0463CF896

Q46376137-C6629A93-3B96-433F-95E4-CE115B82ECC0

Q46376137-DA2FC051-977B-46BB-9AF8-2C09A8C383E0

P304

Q46376137-3B6EA4E1-2424-4114-BC47-9AAFE78E9660

P31

Q46376137-B83F120C-468F-40E0-BB0E-A85D92795481

P356

Q46376137-8B9A0D1A-418C-4794-AF50-5CE55B5CA223

P407

Q46376137-14C2C743-5166-46DE-90E5-A7FCFEAA83C0

P433

Q46376137-8C21849C-143F-4738-943B-78793555D4E1

P478

Q46376137-75A2FDEF-D270-4C98-BA4F-45030716D710

P50

Q46376137-5ACFCA88-7797-4476-9070-17E62CE1D7F4

Q46376137-F61A8AB3-2243-4CF1-8A30-848DA974DB23

P577

Q46376137-81566ABC-2C98-46EF-90BB-11DBFE230511

P5875

Q46376137-9BE5F723-81DE-484A-BD70-7080E8A124E4

P698

Q46376137-89F6CD8B-7369-4F62-AD02-B36E8552C31E

P921

Q46376137-63fdd2c4-63c2-467c-aca3-10cc018227da

Q46376137-6564C477-387B-4866-98AC-A283D4CA5D5B

Q46376137-808C1931-3406-430A-8A39-91D44FCDF747

P356

J.GASTRO.2004.12.050

P1433

Gastroenterology

P1476

Antifibrogenic role of the cannabinoid receptor CB2 in the liver.

@en

P2093

Andreas Zimmer

http://www.w3.org/2001/XMLSchema#string

Ariane Mallat

http://www.w3.org/2001/XMLSchema#string

Boris Julien

http://www.w3.org/2001/XMLSchema#string

Fatima Teixeira-Clerc

http://www.w3.org/2001/XMLSchema#string

Jeanne Tran Van Nhieu

http://www.w3.org/2001/XMLSchema#string

Liying Li

http://www.w3.org/2001/XMLSchema#string

Meliha Karsak

http://www.w3.org/2001/XMLSchema#string

Pascale Grenard

http://www.w3.org/2001/XMLSchema#string

P304

742-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2004.12.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Sophie Lotersztajn

Sophie Lotersztajn

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7969963

http://www.w3.org/2001/XMLSchema#string

P698

15765409

http://www.w3.org/2001/XMLSchema#string

P921

cannabinoid receptor